Multidrug-resistant tuberculosis (MDR-TB): Epidemiology, prevention and treatment

British Medical Bulletin

Volumn 73-74, Issue , 2005, Pages 17-24

  Ormerod, L P ^a,b  

^a ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ANAMNESIS; CLINICAL TRIAL; DISEASE PREDISPOSITION; ERROR; HEALTH PROGRAM; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PHYSICIAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; ISONIAZID; PATIENT COMPLIANCE; RIFAMPIN; RISK FACTORS; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 29644447018     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldh047     Document Type: Review

References (22)

1. Zhang Y, Heym B, Allen B et al. (1992) The catalase-peroxidase gene and isoniazid resistance in M.tuberculosis. Nature, 358, 591-3.
2. Piatek AS, Telenti A, Murray MR et al. (2000) Genetotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapidsusceptibility testing. Antimicob Agents Chemother, 44, 103-10.
3. Telenti A, Imboden P, Marchesi F et al. (1993) Detection of rifampicin resistancemutations in Mycobacterium tuberculosis. Lancet, 341, 647-50.
4. Drobniewski FA, Pozniak AL. (1996) Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. Br J Hosp Med, 56, 204-8.
5. Espinal MA, Laszlo A, Simonsen L et al. (2001) Global trends in the resistance to antituberculosis drugs. N Engl J Med, 344, 1294-1303.
6. Dye C, Espinal MA, Watt CJ et al. (2002) Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis, 185, 1197-2002.
7. Ormerod LP (1997) Chemotherapy of tuberculosis. Eur Resp J, 2, 273-97.
8. Joint Tuberculosis Committee of the British Thoracic Society (1998) Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax, 53, 536-48.
9. Iseman MD (1993) Treatment of multi-drug resistant tuberculosis. N Engl J Med, 329, 784-91.
10. WHO (1996) Guidelines on the Management of Drug-Resistant Tuberculosis. WHO/TB/96.210. Geneva: WHO.
11. Hayward AC, Bennett DE, Herbert J et al. (1996)Risk factors for drug resistance in patients with tuberculosis in England and Wales 1993-4. Thorax, 51 (Suppl 3), A8.
12. Small PM, Shafer RW, Hopewell PC et al. (1993) Exogenous re-infection with multidrug resistant Mycobacterium tuberculosis in patients with advanced HIV disease. N Engl J Med, 328, 1137-44.
13. Salomon N, Perlman DC, Fiedman P et al.(1995) Predictors and outcome of multidrug resistant tuberculosis. Clin Infect Dis, 21, 1245-52.
14. Goble M, Iseman MD, Madsen LA et al. (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med, 328, 527-32.
15. Telzak EE, Sepkowitz K, Alpert P et al. (1995) Multidrug resistant TB in patients without HIV infection. N Engl J Med, 333, 907-11.
16. Herrera D, Cano R, Godoy P et al. (1996) Multidrug resistant tuberculosis outbreak in a HIV ward - Madrid, Spain, 1991-95. MMWR Morb Mortal Wkly Rep, 45, 330-3.
17. Breathnach AS, de Ruiter A, Holdsworth GM et al. (1998) An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. J Hosp Infect, 39, 111-17.
18. Joint Tuberculosis Committee of the British Thoracic Society (2000) Control and prevention of tuberculosis in the United Kingdom: recommendations 2000. Thorax, 55, 887-901.
19. White VL, Moore-Gillon J (2000) Resource implications of patients with multidrug resistant tuberculosis. Thorax, 55, 962-3.
20. Chan ED, Laurel V, Strand M et al. (2004)Treatment and outcome analysis of 205 patients with multidrug resistant tuberculosis. Am J Respir Crit Care Med, 169, 1103-9.
21. Ormerod LP, Horsfield N, Green RM (2002) Tuberculosis treatment outcome monitoring: Blackburn 1988-2000. Int J Tuberc Lung Dis, 6, 662-5.
22. Suarez PG, Floyd K, Portocarrero J et al. (2002) Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet, 359, 1980-9.